| Bioactivity | Cinpanemab (BIIB054) is a human-derived monoclonal antibody that binds to α-synuclein. Cinpanemab can be used for the research of Parkinson's disease[1][2]. |
| Target | α-synuclein |
| Invitro | Cinpanemab 对聚合形式的 α-syn 具有高度选择性，对纤维状重组 α-syn 的表观亲和力至少比单体重组 α-syn 高 800 倍，并且对人 PD 脑组织有强烈的偏好[2]。 |
| In Vivo | Cinpanemab (30 mg/kg; 腹腔注射) 改善 α-syn PFF 接种小鼠模型中的 PD 样表型[2]。 Animal Model: |
| Name | Cinpanemab |
| CAS | 2094516-02-4 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lang AE, et, al. Trial of Cinpanemab in Early Parkinson's Disease. N Engl J Med. 2022 Aug 4;387(5):408-420. [2]. Teng JS, et, al. Immunotherapies for Parkinson's Disease: Progression of Clinical Development. CNS Neurol Disord Drug Targets. 2021;20(9):802-813. |